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Calcium entry through voltage-gated calcium channels has
widespread cellular effects upon a host of physiological pro-
cesses including neuronal excitability, muscle excitation-con-
traction coupling, and secretion. Using single particle analysis
methods, we have determined the first three-dimensional struc-
ture, at 23 A˚ resolution, for a member of the low voltage-acti-
vated voltage-gated calcium channel family, CaV3.1, a T-type
channel. CaV3.1 has dimensions of 115  85  95 A˚, com-
posed of two distinct segments. The cytoplasmic densities form
a vestibule below the transmembrane domain with the C termi-
nus, unambiguously identified by the presence of aHis tag being
65 A˚ long and curling around the base of the structure. The
cytoplasmic assembly has a large exposed surface area that may
serve as a signaling hub with the C terminus acting as a “fishing
rod” to bind regulatory proteins. We have also determined a
three-dimensional structure, at a resolution of 25 A˚, for the
monomeric form of the cardiac L-type voltage-gated calcium
(high voltage-activated) channel with accessory proteins  and
2 bound to the ion channel polypeptide CaV1.2. Comparison
with the skeletalmuscle isoform finds a goodmatch particularly
with respect to the conformation, size, and shape of the domain
identified as that formed by 2. Furthermore, modeling of the
CaV3.1 structure (analogous to CaV1.2 at these resolutions) into
the heteromeric L-type voltage-gated calcium channel complex
volume reveals multiple interaction sites for -CaV1.2 binding
and for the first time identifies the size and organization of the
2 polypeptides.
To date, five different types of voltage-gated calcium chan-
nels (VGCCs)4 have been identified, L, N, P/Q, R, and T, and
classified according to their physiological and pharmacological
characteristics (1–3). On the basis of their electrophysiological
properties, VGCCs can be divided into two classes: high volt-
age-activated (HVA) and low voltage-activated (LVA). T-type
Ca2 channels form the LVA family and are characterized by
their low threshold of activation, small single channel conduct-
ance, slow deactivation, and a low sensitivity to classical block-
ers of HVA channels (4–6). T-type channels have a central role
regulating, for example, cardiac pacemaking of sinoatrial node
cells and tonic firing patterns in neurons (5). Three T-type
channel isoforms have been identified and cloned: CaV3.1,
CaV3.2, and CaV3.3, with each isoform possessing several splice
variants showing distinct functional properties (reviewed in
Ref. 7).
Each VGCC is composed of a pore-forming polypeptide
termed the CaV 1-subunit, with 10 mammalian 1 isoforms
identified, divided into three subfamilies: CaV1–3 (8). Housed
within theCaV1 subunit are the calciumpore, voltage-sensing
apparatus, drug binding sites, and numerous structural deter-
minants required for binding auxiliary subunits and other reg-
ulatory proteins. Analysis of the amino acid sequences and pre-
dicted secondary structure of the T-type channels suggests a
similar topology to the HVA CaV 1 subunits and K and Na
channels, implying that they are evolutionarily related (5).
HVA channels are heteromeric complexes formed by the
CaV 1 polypeptide, with several accessory subunits non-co-
valently bound. For example, the cardiac L-type voltage-gated
calcium channel is formed by the CaV1.2 subunit in association
with the soluble-polypeptide localized to the intracellular side
of the plasmamembrane and a largely extracellular 2 subunit
(9, 10). The -subunit has a role in regulating activation, inac-
tivation, and voltage dependence as well as targeting of CaV1.2
to the plasma membrane. The crystal structure of the core
region of the -polypeptide in complex with a peptide corre-
sponding to the interacting region of theCaV1.2 (AID) has been
described (11, 12), revealing that it is comprised of two
domains, a type 3 Src homology (SH3) domain and a guanylate
kinase-like domain. CaV1.2 is associated, on the extracellular
side of the membrane, with the 2 subunit, the product of
post-translational cleavage of a single gene comprised of a gly-
cosylated extracellular 2 domain linked by disulfide bonds to
the transmembrane  polypeptide, which is also mainly extra-
cellular and glycosylated. Four isoforms of 2 have been iden-
tified (13, 14). The role of the 2 protein is not as well under-
stood as that of the-subunit, but it has been shown to increase
the current amplitude and have effects on inactivation (15). An
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additional membrane-spanning auxiliary subunit, , was ini-
tially thought to be unique to the skeletal muscle LTCC; how-
ever, recent studies have identified neuronal isoforms, although
it remains unclear whether they have any role as calcium chan-
nel subunits (16, 17).
We report here the purification of a recombinant CaV3.1,
leading to the calculation of the first three-dimensional struc-
ture for a member of the LVA channel family. CaV3.1 is formed
by two distinct segments, which we have been able to assign to
the transmembrane and cytoplasmic domains.We have identi-
fied the C-terminal domain that forms a tail that winds around
the base of the structure, providing insights as to how this chan-
nel may be regulated through the binding of accessory/regula-
tory proteins and/or long range conformational movements.
Furthermore, we have been able to utilize this new three-di-
mensional structure to probe the assembly of the polypeptides
forming the cardiac LTCCs after having also calculated a novel
three-dimensional structure for the monomeric form of the
channel purified from bovine heart. At the resolutions
described here, CaV3.1 can be considered analogous to CaV1.2;
see Fig. 1A for a sequence alignment overview. No mandatory
auxiliary subunits for the T-type, LVA, channels have been
identified. However, studies have shown that co-expression of
CaV3.1 with 2 subunits led to a 2-fold increase in T-type-
mediated currents (18), and thus this model may also provide
an insight as to how accessory proteins may associate with
CaV3.1 to exert regulatory effects.
EXPERIMENTAL PROCEDURES
Cav3.1 Expression and Purification—The CaV3.1 rat neuro-
nal clonewas a kind gift fromDr. Edward Perez-Reyes (19). The
baculovirus vector pFastBac-HTa, the Bac-to-Bac baculovirus
expression system, and the Sf9 cells were purchased from
Invitrogen. CaV3.1 containing aC-terminal c-Myc and decahis-
tidine (His10) tag (20)was subcloned into the baculovirus vector
pFastBac-HTa. Recombinant baculoviruses were generated
using the Bac-to-Bac system (Invitrogen). Sf9 insect cells were
cultured in TNM-FH medium (Sigma T3285) supplemented
with 10% (v/v) fetal bovine serum and were split when conflu-
ent. For protein expression, Sf9 cells, 70–80% confluent, were
infected with recombinant baculoviruses at a multiplicity of
infection of 1–2. They were then incubated at 27 °C for 72 h.
Virus-infected Sf9 cells expressing theCaV3.1were harvested
72 h after infection by centrifugation at 1000 g for 5min. The
resulting cell pellets were resuspended in 10 ml of buffer con-
taining 20 mM Tris, pH 8.0, 150 mM NaCl, and 1 mM DTT. All
buffers also contained protease inhibitors in the form of Com-
plete EDTA-free protease inhibitor mixture (Roche Applied
Science), with one tablet dissolved for every 50 ml of buffer.
Cells were lysed by sonication for 3  30 s. The mixture was
then centrifuged at 1000  g for 5 min to remove the large
particulate matter. The resulting supernatant, containing the
Sf9 cell membranes, was then centrifuged at 50,000 g for 1 h.
The pellet was then resuspended in 10 ml of buffer containing
20mMTris, pH8.0, 150mMNaCl, 20mM imidazole, 1mMDTT,
1% (w/v) CHAPS, and protease inhibitors and incubated for 1 h
on a rolling platform at 4 °C. The solubilizedmembrane protein
then underwent centrifugation at 20,000 g for 30 min at 4 °C
to clear any unsolubilized material. The resulting supernatant
was diluted 1:1 with buffer containing 20 mM Tris, pH 8.0, 150
mM NaCl, 20 mM imidazole, and 1 mM DTT and applied to a
1-ml Ni-NTA column (HIS-Select nickel affinity gel (Sigma)),
which had been pre-equilibrated with a buffer containing 20
mM Tris, pH 8.0, 150 mM NaCl, 20 mM imidazole, 1 mM DTT,
0.5% (w/v) CHAPS. The gel matrix was washed with 5 volumes
of equilibration buffer: 20 mM Tris, pH 8.0, 150 mM NaCl, 20
mM imidazole, 1 mM DTT, 0.5% (w/v) CHAPS. The protein
solution was then added to the matrix, and this was left for 1 h
on a rolling platform at 4 °C. The columnwas thenwashedwith
20 volumes of equilibration (wash) buffer, and finally, the
boundproteinwas eluted by the addition of 1 columnvolumeof
equilibration buffer containing 350 mM imidazole. This final
step was repeated four times, and thus four eluted fractions
were collected. The eluted protein was concentrated using a
Centricon YM-50, applied to a size exclusion column
(Sephacryl S-200), and eluted off using the buffer above (with-
out the imidazole and with 50 mM NaCl). CaV3.1-containing
fractions were applied to a preswollen microgranular anion
exchanger diethylaminoethyl (DEAE) cellulose (DE52, What-
man). CaV3.1 was eluted using a step NaCl gradient (25–500
mM, using 25 mM increments). SDS-PAGE and Western blot-
ting (anti-Cav3.1, Santa Cruz Biotechnology sc-25690) were
employed to determine the purity and characterize the purified
protein at each step with protein eluting between 250 and 350
mMNaCl from the DEAE-column found to be pure CaV3.1 (see
Fig. 1A).
Cardiac LTCC Purification—Sarcolemmal membranes were
prepared from bovine heart according to Ref. 21. All buffers
throughout the purificationwere supplementedwith a protease
inhibitor mixture containing 0.1 mM phenylmethylsulfonyl flu-
oride, 1 mM benzamidine, 1 M pepstatin A, and 1 M L-trans-
epoxysuccinyl-leucylamide-(-4-guananido)-butane (E64). As
described previously (22), LTCCs were solubilized from the
sarcolemmal membranes (protein concentration of 2 mg/ml)
by incubation with 1% (w/v) digitonin (detergent:protein 5:1),
in 20 mM Tris, pH 7.5, 2 mM CaCl2, for 45 min with gentle
agitation at 4 °C. The solubilized protein was then loaded onto
a DEAE-column (20 ml) equilibrated with the solubilization
buffer. Unbound protein was removed by washing with 1.5 col-
umn volumes of 0.1% (w/v) digitonin in 20 mM Tris, pH 7.5,
followed by a second wash with 1% (w/v) decyl--D-maltoside
substituted for the digitonin. Protein was then eluted from the
column with a linear NaCl gradient (0–0.5 M) in 1% w/v decyl-
-D-maltoside, 20 mM Tris, pH 7.5, 2 mM CaCl2. The LTCC-
containing fractions were then concentrated using a Centricon
YM-50 and applied to a size-exclusion column (Sephacryl
S-300). The channel-containing fractions were then applied to
a wheat germ agglutinin (WGA)-column, and the purification
procedure followed that described in Ref. 22. Purified cardiac
LTCC preparations were examined by SDS-PAGE, and native
gels were as described in Ref. 23. Protein bands from gels were
transferred to nitrocellulose using a Bio-Rad Transblot appara-
tus. Monoclonal antibodies against the cardiac LTCC 2 sub-
units were purchased from Abcam, and antisera and affinity-
purified antibodies raised against a-subunit peptide (Ab2491)
were prepared as described previously (23, 24).
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Electron Microscopy and Image Analysis—Samples were
examined using standard negative staining techniques with 2%
(w/v) uranyl acetate. Images of the LTCC complex and CaV3.1
were recorded between a 0.55–0.96 m and 0.65–1.05 m
defocus range, respectively, on a Tecnai 12 transmission elec-
tron microscope operated at 100 kV, at a calibrated magnifica-
tion of47,800.Micrographswere scanned using an IMACON
scanner at 3.6 Å/pixel at the specimen level. CaV3.1 and cardiac
LTCC samples were checked for homogeneity and presenta-
tion of different views. Matrix analysis of sampling over Euler
angles, , , and , showed a good coverage of three-dimen-
sional space for each data set (not shown). The contrast transfer
function (CTF) was determined for each image using CTFIT
(part of the EMAN software). As discussed by Adair et al. (25),
images were corrected for phase effects only. The resolution of
the final three-dimensional volumes for Cav3.1 and the cardiac
LTCC were assessed following established procedures (26). In
brief, each data set was divided into two, with volumes calcu-
lated for the two subsets, and the resolution was estimated by
the Fourier shell correlation (FSC) coefficient with the resolu-
tion limit taken to be where the FSC value fell below 0.5. All
models were generated using the UCSF Chimera program.
Three-dimensional Reconstruction of Recombinant Cav3.1—
The three-dimensional structure of the recombinant CaV3.1
was generated using the common line projection matching
methods employed in EMAN (27) with no symmetry applied
(C1). Three-dimensional reconstructions of small asymmetric
proteins are complex, and rigorous experimentation must be
undertaken to ensure that the features in the final model are
robust. A wide variety of starting models were tested including
Gaussian blobs, transmembrane domain of KV1.2 (PDB entry
2R9R, edited), and the full KV1.2 crystal structure (2R9R) fil-
tered to an appropriate resolution. In all reconstructions the
principal structural features were consistent, indicating the
fidelity of the final three-dimensional reconstruction. Approx-
imately 11,500 particles were selected interactively using the
graphical interface boxer (EMAN image processing software)
into a box of 64  64 pixels (230  230 Å). Particles were
band-pass-filtered and centered, and a preliminary three-di-
mensional model was calculated from a set of unbiased refer-
ence-free class averages showing different orientations of the
complex (using the refine2d.py program under EMAN). The
three-dimensional model was iteratively refined at each step
using a projection matching routine, whereby projections with
uniformly distributed orientations of the preliminary three-di-
mensional model were used as references for classification of
the raw data set, with the class averages from this step used to
construct a new three-dimensionalmodel. Refinementwas car-
ried out with an angular coverage of 7° generating 388 classes
containing between 10 and 48 particles per class. The final
reconstruction included 86% of the selected images. Conver-
gence, i.e. stabilization of the three-dimensional structure, was
monitored by examining the FSC of the three-dimensional
models generated from each iteration.
The presence of the C-terminal His tag allowed labeling of
the CaV3.1 C terminus using Ni-NTA-gold (Nanoprobes Inc).
Excess Ni-NTA-gold was added to the purified CaV3.1 and
incubated for 3 h. Aliquots were then stained with uranyl ace-
tate as above. Approximately 4,500 CaV3.1 particles with a gold
label associated were selected. The class averages shown in Fig.
3 illustrate that a good sampling of different orientations of
labeled CaV3.1 was observed. The same initial start model
employed for the three-dimensional reconstruction of the unla-
beled CaV3.1 was used for the gold-labeled channel.
Three-dimensional Reconstruction of Purified Cardiac
LTCCs—The three-dimensional structure of the cardiac LTCC
was generated using the samemethodology as described above,
determined with no symmetry imposed, i.e.C1. Approximately
4,300 particles were selected interactively using the graphical
interface boxer (EMAN image processing software) into a box
of 88  88 pixels (316  316 Å). Particles were band-pass-
filtered and centered, and a preliminary three-dimensional
modelwas calculated froma set of unbiased reference-free class
averages showing different orientations of the complex. The
three-dimensional model was iteratively refined at each step
using a projection matching routine, carried out with an angu-
lar coverage of 10 degrees generating 179 classes with between
7 and 42 images per class. The final reconstruction included
87% of the selected images. As described above, to ensure that
the features of the resulting C1 volume were consistent, several
different start models from class averages derived from startnr-
classes and refine2d.py, as well as using a sphere (makeini-
tialmodel.py), were employed. Fourier shell correlation
between eachmodel was used to determine convergence to the
finalmodel. A lowpassGaussian filter to 25Åwas applied to the
final three-dimensional volume in accordance with the resolu-
tion assessment.
Cardiac LTCC Labeling—Concanavalin A (Sigma) (stock 5
mg/ml in 10 mM Hepes, 50 mM NaCl, 1 mM CaSO4, 1 mM
MnCl2, pH 7) was added in a 3-fold excess to the purified car-
diac LTCC (following the method described in Ref. 28) for 30
min on ice. Samples were then examined by transmission elec-
tron microscope after staining with 2% (w/v) uranyl acetate.
Micrographs were scanned as above, and LTCC-Con A conju-
gates were selected (box size 104  104 pixels; 374  374 Å),
aligned, and classified using standard programs in the SPIDER
software package (29).
RESULTS
CaV3.1 was expressed and purified from Sf9 cells. CaV3.1 is a
small (250-kDa, rat) asymmetric protein composed of 24
putative transmembrane segments, grouped into four domains,
which are connected by intracellular loops, with a large (46
kDa) cytoplasmic C-terminal domain. We have previously
characterized this expressed protein and shown it to be func-
tional (20). Serial chromatographic techniques were employed,
including nickel affinity gel, to exploit the presence of the poly-
histidine tag. Size exclusion and ion exchange steps were also
introduced to further purify the sample, leading to a single band
on a SDS-PAGE at 250 kDa, corresponding to the predicted
molecular mass of CaV3.1 (Fig. 1B, lane 1). The identity of the
purified protein as CaV3.1 was confirmed by Western blotting
methods (Fig. 1B, lane 2, anti-CaV3.1; lane 3, anti-His). Approx-
imately 50 g of highly purified CaV3.1 protein was isolated
from 49 mg of Sf9 cells after sonication.
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Structure of Cav3.1 at 23 Å—Single particle analysis has
proven particularly suitable for structural studies of large mac-
romolecular complexes such as the ribosome (for review, see
Ref. 30) and proteins with complex symmetry e.g. viruses (31);
however, there are also a number of reports for successful
reconstructions of relatively small asymmetric proteins (e.g.
Refs. 25, 32–34). Examination of micrographs of purified
CaV3.1 found a homogeneous population of particles, present-
ing multiple views of the channel. Encouragingly, square-
shaped particles with a side length of100 Åwere occasionally
observed (indicated on Fig. 1C) thatmay represent a view of the
channel perpendicular to the membrane plane in keeping with
the putative pseudo four-fold symmetry of the transmembrane
domains. The Fourier common lines projection-matching
method was employed using the EMAN software package (27)
to calculate a three-dimensional structure. In total, 11,500
Cav3.1 particles, ranging in size from 80 to 120 Å, were
selected. Fig. 1D presents examples of class averages and corre-
sponding reprojections of the final three-dimensional volume,
illustrating that the structure is consistent with the class aver-
ages. Image 1 shows a structure that is 115 Å in length, nar-
rowing to one end and 85 Å at the widest point. The image
below is slightly shorter and wider with two distinct domains
resolved. The complexes in rows 3 and 4 are almost square-
shaped,85 95 Å, and are characterized by a central region
of low density (i.e. averages appear slightly darker in the mid-
dle). The arrow on image 4 highlights a small density we have
termed the tail that protrudes from the body of the complex.
Although image 5 is similar in shape and size to that presented
in row 3, it does not display amid region of low density and thus
likely represents a different view of the complex. Image 6 shows
a class average that is consistent with the observation of tetrag-
onal particles with side lengths of 100 Å. The Fourier shell
correlation plot shown in Fig. 1E indicates that the resolution of
the final three-dimensional volume is23 Å at a correlation of
0.5.
The three-dimensional reconstruction of purified CaV3.1
(Fig. 2) yielded a complex115Å tall with a width and depth of
FIGURE 1. Characterization, purification and image analysis of the T-type voltage gated calcium channel Cav3.1. A, schematic overview of a sequence
comparisonof voltage-gated calciumCa2 channel subunits CaV1.2 andCaV3.1. Sequence alignmentwas carried out usingClustalW (37). Solid regions indicate
aligned sequences (black blocks correspond to the transmembrane helices); extracellular loops comprising 10 amino acids are not depicted. B, lane 1,
silver-stained 10% SDS-PAGE of purified recombinant CaV3.1 revealing a single polypeptide band at250 kDa. Lane 2, identification of the purified Cav3.1 by
Western blotting (anti-CaV3.1, Santa Cruz Biotechnology sc-25690). Lane 3, Western blot of the purified Cav3.1 using an anti-His (Santa Cruz Biotechnology)
antibody revealing a single protein product (recombinant Cav3.1 with a C-terminal His tag) at250 kDa. C, field of negatively stained (2%w/v uranyl acetate)
recombinant CaV3.1 showing white protein particles presenting a range of orientations85–115 Å in size. The asterisk indicates a small area of aggregation
that is easily distinguishable from the single CaV3.1 complexes. The black arrows indicate square-shaped particles with a side length of100 Å. D, column I,
examplesof reference-free class averagesobtainedbyalignmentof the rawdata that are representativeof the rangeofmultiple orientations sampled (box size
230 230 Å). Column II, corresponding back projections of the final three-dimensional volume illustrate that the structural features are consistent with those
shown in the class averages. E, Fourier shell correlation plot indicating at a correlation of 0.5 that the three-dimensional CaV3.1 structure is at a resolution of
23 Å.
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85 95 Å. A putative side view of CaV3.1 is presented in Fig.
2A. It is comprised of two distinct sections: an upper compact
domain labeledM50–60 Å in height and 85 95 Å across as
viewed from the top (Fig. 2, A and D) and a lower portion
labeled C formed from a number of densities (Fig. 2, B and C).
Fig. 2E shows that the structure of CaV3.1 is open from the
bottom and reveals that the domain we identified as the tail in
class average 4 (Fig. 1D) is65Å long and curls around the base
to form a horseshoe shape. The three-dimensional structure of
CaV3.1 is displayed to encapsulate a protein mass of320 kDa
(including detergent micelle and residual lipid). It is estimated
that the amount of detergent associated with purified intrinsic
membrane proteins increases the mass of the protein, depend-
ing on the detergent, by a factor of 0.3–1.5 (35). Therefore, the
structure is also presented (Fig. 2, F andG) at two other volume
thresholds. It can be seen (Fig. 2F) that there are few differences
between the structural features, except that at the lower thresh-
old, the tip of the tail forms a contact with the lower portion of
domain M, as indicated by the arrow. At a higher threshold
(corresponding to a protein mass of 230 kDa, Fig. 2G dis-
played in red surface render), the
global features and characteristics
identified in panels A–F remain
consistent.
Orientation of Cav3.1—Using Ni-
NTA-gold (Nanoprobes Inc.), we
have labeled the polyhistidine tag at
the C terminus of CaV3.1 to identify
its position within the three-dimen-
sional structure. The Ni-NTA-gold
conjugate is visualized as an elec-
tron-dense black globular domain
1.8 nm in diameter, under the
conditions employed here, and has
the advantage of being able to bind
closely to the His tag because there
are no additional proteins attached.
We calculated a new three-dimen-
sional structure from 4,500 CaV3.1
particles with a gold label bound,
using the same starting model and
refinement parameters as those
used for determining the unlabeled
structure in Fig. 2. The principal
structural features of the labeled
CaV3.1 matched well to those of the
unlabeled structure illustrated by
the close similarity between some
examples of class averages from
both data sets shown in Fig. 3A. The
two volumes were superimposed,
with the labeled structure displayed
using negative thresholds to visual-
ize the electron-dense gold conju-
gate. Different views of CaV3.1 are
shown in Fig. 3, B–E, revealing the
gold to be nestled between the tail
and body of the complex and bound
to the lateral portion of the tail. Thus we propose that this
domain corresponds to the C terminus of CaV3.1. Moreover,
the approximate volume encompassed by the tail domain, at
thresholds displayed here, corresponds to a mass of 50 kDa
(based upon an average protein density of 1.22 g cm3 or 0.735
Da/Å3 (36)), which is in keepingwith the predictedmass of46
kDa (amino acids 1823–2254) of the cytoplasmic C-terminal
domain extending from transmembrane (TM) IVS6.
Fitting of the Crystal Structure of Kv1.2 to the Transmem-
brane Domain of Cav3.1—The transmembrane domain of
KV1.2 (PDB entry 2A79), equivalent in terms of size and
predicted organization to the TM regions of CaV3.1, can be
fitted into domain M (Fig. 3, F–I). Fig. 3F shows the top view
of CaV3.1, and although a central pore is not resolved in the
outer surface of the complex, a section taken through
domain M (in the position indicated in Fig. 3I by the dashed
line) reveals that the interior is formed by 3–4 domains orga-
nized in such a way that there is a central area of low density
(Fig. 3J), which is consistent with the predicted topology of
the TM domain. It should be noted that the definition of the
FIGURE 2. Three-dimensional structure of Cav3.1 at 23 Å. A, putative side view of CaV3.1, displayed for a
protein mass of320 kDa, revealing a structure115 Å tall and85–95 Å across. The complex is formed by
two domains we have termedM and C, as illustrated on the figure. B and C, rotation of this view around the y
axis reveals further details with C showing that the density we have called the tail is65 Å in length, extends
out, and curls around the base of the structure. D, a view of the upper surface of domain M revealing it to be
relatively flat,85 95 Å in size. E, rotation of the view in D 180° around the x axis to show the base of the
structure. F, three-dimensional structure of CaV3.1 displayed at two volume thresholds; turquoise solid surface
corresponds to a protein mass of 320 kDa, and green mesh corresponds to a protein mass of 620 kDa.
G, three-dimensional structure of CaV3.1 displayed at two volume thresholds; the red solid surface (230 kDa)
and turquoise mesh (320 kDa) show that the principal structural features are consistent between maps,
although at higher thresholds, the tail is separated from the other cytoplasmic protein domains by a small gap
indicated by the arrow in F.
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interior of a protein structure applying negative staining
techniques relies on the ability of the stain to penetrate the
volume and is also influenced by the hydrophilic nature of
the internal environment, and as such, caution should be
taken when interpreting internal features. As would be
expected, there is not an exact fit between the two as not only
are we comparing a calcium channel with a potassium chan-
nel, but there will also be conformational effects upon the
TM helices due to the presence of the cytoplasmic assembly
in CaV3.1. However, this comparison serves to illustrate that
the TM domain of KV1.2 is accommodated within the sec-
tion of CaV3.1 we have labeled M
and fits in terms of both shape and
overall size.
Fitting of Cav3.1 with the Three-
dimensional Structure of the Car-
diac L-type Voltage-gated Calcium
Channel—A schematic representa-
tion of a sequence alignment of
CaV1.2 and CaV3.1 is shown in Fig.
1A. There is an overall sequence
identity of 19% between the two
HVA and LVA channels (ClustalW
(37)), although analysis of the indi-
vidual domains finds a much higher
match between the four repeat TM
segments (I–IV). Using ClustalW,
the average alignment between each
TM segment is 40%, with the
T-Coffee scoring system (available
from the EMBL-EBI site) calculat-
ing similarity scores to be between
86 and 94%. At the resolutions
attained using negative staining and
single particle analysis methods, the
three-dimensional volume reported
here for CaV3.1 can used to repre-
sentCaV1.2 and thus should provide
some insights as to how the cardiac
LTCC is formed by several other
subunits associating with CaV1.2.
Similarly, this type of modeling
could inform upon how CaV3.1
might bind auxiliary proteins, as
although no auxiliary subunits have
been identified, as discussed above,
there is evidence to suggest that
2-1, when co-expressed with
T-type channels, results in enhance-
ment of the calcium channel cur-
rents. To carry out this analysis, we
have calculated a new three-dimen-
sional structure for a monomeric
form of the cardiac LTCC.
Purification of Cardiac LTCCs—
Previously, we have reported the
isolation of dimeric forms of the
skeletal and cardiac muscle LTCCs
(22).We have now prepared LTCCmonomers by the introduc-
tion of two additional steps to the purification procedure: (i) a
detergent exchange step replacing digitonin with decyl--D-
maltoside (1% w/v) during the first chromatographic step and
(ii) size-exclusion chromatography. Presented in Fig. 4A is an
SDS-PAGE (silver-stained) of the purified LTCC showing four
main bands at240 kDa (1), 130 kDa (2),  (60 kDa), and
 (30 kDa). The silver-stained band corresponding to the 2
subunit is very faint; however, Western blotting with a mono-
clonal anti-2 antibody (Abcam) confirmed the presence and
identity of this polypeptide with a molecular mass of130 kDa
FIGURE 3. Labeling of the C terminus of Cav3.1 and assignment of the transmembrane and cytoplasmic
assemblies. A, Ni-NTA-gold was incubated with purified recombinant CaV3.1 to identify the position of the
polyhistidine-taggedC terminus. The top panels show a sample of some class averages (row I) and correspond-
ing reprojections (row II) of the final three-dimensional volume of Ni-NTA-gold-labeled CaV3.1. The Ni-NTA-
bound conjugate is electron-dense, and the gold particle is visualized as a black domain2 nm in diameter
associated with the white protein density. The bottom panels show very similar class averages from the unla-
beled CaV3.1 data set (row Iwith back projections presented below in row II). Images in column 1 show a view
that likely corresponds to the cytoplasmic side with the gold bound between two densities separated by a
cavity and at one end. Column 3 shows the gold to be nestled between the body of the complex and the tail
comparable with the view shown in panel C. Column 5 shows an elongated (side view115 Å long axis) with
the gold toward one end (the class averages from the labeled and unlabeled data set are not aligned with
respect to each other). Images in columns 2, 4, and 6 show views of the complex that are similar to the
orientations presented in panels C, D, and E. Box size 230 230 Å. B–E show the three-dimensional volume
of the unlabeled CaV3.1 with the structure of CaV3.1 labeled with Ni-NTA-gold superimposed, with the main
structural featuresmatched and the labeledmap displayed at negative thresholds (gold density) to display the
position of the Ni-NTA-gold with respect to the protein structure. F–J illustrate the matching of the crystal
structure of the potassium channel KV1.2 (TMdomain) to the three-dimensional structure of CaV3.1. F, putative
top view of the complex showing that the crystal structure of KV1.2 (PDB entry 2A79), purple ribbon, is accom-
modatedwithin domainM.G, base of the complex viewed perpendicular to themembrane, revealing that the
pore of Kv1.2 is open to the intracellular milieu through a passageway formed by domain C. The views shown
in H and I illustrate that the TM domain of KV1.2 is also compatible with the height of domain M, and thus the
putative position of the lipid bilayer is proposed. J, a slice taken through the top of domain M as orientated in
panel I at the position indicated by the dashed line. The section reveals between 3 and 4 protein densities
arranged at the corners of the roughly square-shaped slice surrounding a region of low density. Red, yellow,
green, pink, and blue correspond to thresholds at 6, 5, 4, 3 and 2 	 above the mean density.
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(Fig. 4A, lane 3). Silver staining is not a quantitative method,
with the intensity of the band being dependent upon a number
of physicochemical properties of the protein. In particular, gly-
cosylated proteins often do not stain well, e.g. Ref. 38. Gel elec-
trophoresis under non-denaturing conditions revealed that the
purified protein has a molecular mass of540 kDa (Fig. 4B), in
contrast to our previous preparations of both the cardiac and
the skeletal LTCCs describing dimers of mass 800 kDa (22,
23). As discussed above, the association of detergentmicelles to
integral proteins upon solubilization from the native mem-
brane leads to an increased protein mass, and thus 540 kDa
can be equated to a monomeric cardiac LTCCwith a predicted
molecular mass of 450 kDa with additional detergent and
residual lipid bound. Themolecularmass of the skeletal muscle
LTCC monomer was also reported to be 550 kDa (39).
Although the skeletal muscle LTCChas an additional  subunit
(30 kDa), CaV1.2 is believed to be larger than CaV1.1 by about
30 kDa, and thus it would be predicted that the molecular
masses for both complexes would be roughly similar.
Three-dimensional Structure of the Cardiac LTCCMonomer—
Shown in Fig. 4C is a sample area of a micrograph of nega-
tively stained purified cardiac LTCCs showing particles ranging
from130 to 170 Å in size. Above the sample micrograph area
are some examples of the raw particles presenting different
views of the LTCC. A good sampling of multiple views of
the LTCC complex was found, permitting implementation of the
Fourier common lines projection matching method, using the
EMAN software package (27), to determine the LTCC complex
three-dimensional structure. Examples of class averages pre-
senting different views of the complex are shown in Fig. 4Dwith
the plot in Fig. 4E showing that the resolution, estimated by the
FSC method, for the final LTCC monomer three-dimensional
structure is at25 Å.
The three-dimensional volume of the cardiac LTCC mono-
mer (Fig. 5, A–F) shows a structure comprised of two distinct
portions, a heart-shaped body with a density we have termed
the “finger” domain extending out from the body, in keeping
with the structural features we identified in studies of the dimer
form of the LTCC. The body is170 Å in height with a width
and depth of 140 and 120 Å, respectively, being wider at the
top, tapering toward the base (Fig. 5,A andB). The finger can be
seen to protrude fromadensity at the tip of the body domainwe
FIGURE 4. Purification and image analysis of cardiac LTCCs. A, silver-stained SDS-PAGE of purified cardiac LTCC revealing a composition of four protein
bands (lane 1) with molecular masses of 240, 130, 55, and 30 kDa corresponding to CaV1.2 (1), 2-, -, and -polypeptides. Lane 2, Western blot with
anti--serum (23), and lane 3, anti-2 (Abcam).B, silver-stainednativegel of thepurified LTCCwith theprincipal proteinbandat540 kDa.C, field of negatively
stained (2% w/v uranyl acetate) purified cardiac LTCC revealing a population of particles presenting a range of orientations100–170 Å in size, as indicated
in the boxes. In one of the images, the complex can be seen to be roughly ellipsoidal with a protruding density indicated by an arrow. Examples of rawparticles
of the cardiac LTCCs are shown above (box size: 302  302 Å). D, class averages (left-hand column) and corresponding reprojections of the final three-
dimensional cardiac LTCC volume (right-hand column) illustrating a good correlation (box size: 302 302 Å). The class average in panel 1 shows an almost
heart-shaped complex with a height of160 Å that is125 Å wide at the top narrowing toward the base. A small protuberant domain is observed in class
averages in panels 3 and 4, as indicated by the arrows. Class averages in panels 5 and 6 show views of the complex125 and 100 Å in diameter. Several of the
class averages also appear to have a central region of low density. The corresponding back projections of the final three-dimensional volume are presented in
the adjacent column, illustrating good agreement between the two. E, Fourier shell correlation plot indicating at a correlation of 0.5 that the cardiac three-
dimensional LTCC structure is at a resolution of 25 Å.
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have termed the “nose,” a feature we also identified in the car-
diac LTCC dimer volume (22). Further details of the finger seg-
ment can be seen in Fig. 5, C–E, showing that it extends away
from the body by 25 Å and is folded into a “hook”
conformation.
Comparison of the Cardiac LTCCMonomer with the Skeletal
Muscle Form—The structure for the cardiac LTCC described
here allows for a direct comparison with the skeletal muscle
LTCC calculated from cryo-EM images (39) emd-1069.map
(available through the EmDep Deposition Tool). As shown in
Fig. 6A, there is a good match in terms of overall size between
the two LTCCs (cardiac displayed in pink mesh and skeletal
portrayed in green solid surface). In particular, the length of the
cardiac finger density maps well onto the “leg” domain of the
skeletal muscle LTCC, with the angle of protrusion and exten-
sion away from the main body of the complex also matching.
Furthermore, it can be seen that the width of the two structures
is similar, except that the skeletal muscle volume is more
rounded when compared with the cardiac LTCC, which is
tapered toward the base of the volume; this may be due to the
absence of the  subunit in the cardiac LTCC assembly.Match-
ing this new structure with the cardiac dimer volume (22) is less
straightforward because association of twomonomerswill have
led to some conformational changes.
Labeling and Orientation of the Cardiac LTCC Monomer
within the Sarcolemmal Membrane—Following the strategy
described in Ref. 28, we employed concanavalin A (ConA) to
label the extracellular portion of the cardiac LTCC complex.
ConA at pH 7 is known to form an asymmetric tetramer (40);
analysis of theConA sample by negative staining found ahomo-
geneous population of particles ranging from 3 to 6 nm in size
(data not shown). In this form, ConAhas exposed carbohydrate
binding sites that can associate with the N-linked oligosaccha-
ride moieties of the 2 subunit of
the cardiac LTCC. Examination of
samples of tetrameric ConA with
purified cardiac LTCC by transmis-
sion electron microscopy after neg-
ative staining allowed selection of
LTCC-ConA complexes, and using
reference-free alignment and classi-
fication algorithms, a series of class
averageswas generated, examples of
which are presented in Fig. 6B. Class
averages in panels 1 and 2 show views
of the LTCC with the finger domain
(indicated by the white arrow)
extending out to the right of the body
with a further density (Con A) bound
(indicated by the black arrow) to the
finger. Examination of the three-di-
mensional structure suggests that
these views represent partial face-
on orientations of the complex with
the ConA associating with a portion
of the finger density. Class averages
in panels 3 and 4 show the putative
side view of the LTCC complex
(170 Å tall), with the ConA attached to the wider end of the
body in a manner that looks distinct from the labeling of the
finger domain. Because the 2 and  polypeptides are both
highly glycosylated, the identification of two possible binding
sites is reasonable. These data support our previous interpreta-
tion of the cardiac LTCCdimer three-dimensional volumewith
the finger domain and tip of the complex representing the
extracellular portion of the cardiac LTCC corresponding to the
2 and  polypeptides.
Employing our novel structure for CaV3.1 reported here,
we have modeled this volume to represent CaV1.2 in the new
cardiac LTCC monomer map. Fig. 7, A and B, show putative
side views of the cardiac LTCC (pink mesh) with the CaV3.1
volume (turquoise solid iso-surface) and crystal structures
for KV1.2 (PDB entry 2A79) (magenta helices) and -core
(PDB entry 1T3L) (blue helices, AID domain in red) accom-
modated within the complex volume. As would be predicted,
there is some overhanging CaV3.1 density in the region
assigned to the cytoplasmic domain, but this agrees with the
differences in the predicted topology of the two channel pro-
teins (Fig. 1A). Fig. 7C shows an orientation of the cardiac
LTCC to illustrate a perforation in the outer surface of the
structure that leads to an inner chamber. CaV3.1 is not
shown on this figure for clarity, but it can be seen from Fig. 2
that the cytoplasmic domains are punctuated by a number of
orifices that, when modeled as shown here, line up with the
side hole in the LTCC complex.
The structures shown in Fig. 7 also provide new information
as to howboth the2-subunit and the-subunitmay associate
with CaV1.2. Subtraction of the CaV3.1 map from the LTCC
three-dimensional structure leaves a volume that correlates to a
protein mass of 210 kDa, which equates to the combined
mass of the - and 2-polypeptides (taking into account that
FIGURE 5. Three-dimensional structure of the monomeric cardiac LTCC displayed at a threshold to
encompassaproteinmassof540kDa.A, theputative side view (i.e.perpendicular to themembraneplane)
of the cardiac LTCC monomer shows a complex170 Å tall and135 Å across at the widest point tapering
toward the base. B–D, rotation of the view in A around the y axis counterclockwise reveals that the finger
domain is90 Å in length and has a hook-shaped formation comprised of several interconnecting domains.
The orientation shown in B reveals that the structure, behind the finger domain, is open to the extracellular
milieu through a series of gaps in the outer surface. A small perforation in the outer surface (labeled hole) that
forms a tunnel leading into the center of the structure can be seen in B and C. E, rotation of the view presented
in panel A around the x axis 90° away from the plane of the page reveals the top of the structure with a density
we have termed the finger domain extending out from the body. F shows the base of the complex.
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CaV3.1 is 20 kDa larger than CaV1.2). We propose, in agree-
ment with labeling studies, that the region above the CaV3.1
volume extending up to the nose and around to the finger
domain corresponds to 2 (Fig. 7, D–G, 2 shown in green).
This orientation places the intracellular -subunit toward the
narrow end of the LTCC complex partially fitting into the
pocket formed by the cytoplasmic domains of CaV3.1. For clar-
ity, similar views of the LTCC are shown in panels D and Ewith
only the KV1.2 crystal structure shown.
DISCUSSION
The data presented here show the first views of a T-type
voltage-gated calcium channel polypeptide, at low/medium
resolution. The placement of the KV1.2 crystal as shown in Fig.
3 is consistent with the lower domain (termed C) being formed
by the cytoplasmic segments and in agreement with experi-
ments identifying the C-terminal domain, by virtue of its His
tag. As shown in Fig. 1A, CaV3.1 has two large cytoplasmic
domains forming loops between IS6 and IIS1 (38 kDa, amino
acids 396–743) and IIS6 and IIIS1 (31 kDa, amino acids 965–
1272) with a smaller loop of 7 kDa between IIIS6 and IVS1
(amino acids 1538–1610). The three-dimensional volume of
CaV3.1 shows that the C domain is indeed formed by several
large densities extending below the region assigned to the lipid
bilayer to form a vestibule that is in many respects reminiscent
of the organization of the intracellular domains of the voltage-
sensitive sodium channel (34). Furthermore, the organization
proposed here shows that the pore of the KV1.2 channel lies
directly above the chamber formed by the putative cytoplasmic
domains (Fig. 4B), thus providing a passageway for calcium ions
to exit through into the cytosol. Intracellular loops of Ca2, K,
and Na channels have been suggested to form domains that
act as a “ball and chain” or “hinged lid” that play central roles in
channel gating as well as binding sites for  auxiliary subunits.
Current data suggest that the T-type channel inactivation proc-
ess probably also operates by involving multiple domains, i.e.
the S6 helix in repeats I and II (41, 42), the selectivity filter (43),
and the C terminus (44). A recent report has also determined
that the proximal region (first 55 amino acids) of the I-II loop
functions as a gating particle with the distal portion effecting
trafficking to the plasmamembrane (45). Although the I-II and
II-III cytoplasmic loops are not completely resolved from each
other in the three-dimensional volumepresented here, they can
be seen to form ridges of protein density (e.g. Fig. 2B). This
arrangement of the intracellular domains forms an exposed
surface that is accessible for forming structural associations
with regulatory proteins to exert cellular effects. For example
protein kinase C has been described to stimulate CaV3.1 with
effects localized to the II-III loop (46).
We have also reported a three-dimensional structure for a
monomeric cardiac LTCC, in contrast to the channel dimers
described previously (22). The isolation of a monomeric car-
diac, LTCC, cannot be solely attributed to the detergent
exchange step because purification of the skeletal muscle chan-
nel monomers also employed digitonin (39) but probably
relates to the number of purification steps, the endogenous lip-
ids co-purified, and channel complex stability. Our experiences
suggest that lipid association plays a role, and we have previ-
ously described how dilution with buffer not containing lipids
coupled with a further size exclusion chromatography step led
to a partial dissociation of the cardiac dimers tomonomers (22).
It may be, therefore, that the introduction of the detergent
exchange step has tipped the monomer-dimer balance in the
subsequent purification steps we employed, resulting in less
co-purifying lipid and thus favoring the monomer form.
We noted that both the finger of the cardiac LTCC and the
tail domain of CaV3.1 have similar characteristics in that they
FIGURE 6. Comparison of the three-dimensional structure of the cardiac
LTCCmonomerand themonomeric skeletalmuscle LTCCand labelingof
the glycosylatedmoieties of the purified cardiac LTCC.A, matching of the
cardiac LTCC monomer (pink mesh) with the three-dimensional volume
reported byWolf et al. (39) (green iso-surface), illustrating that both structures
have a similar overall height and width with a good correlation between the
size, conformation, and orientation of the finger domain of the cardiac LTCC
describedhere and the legdensity of the skeletalmuscle LTCC.B, examples of
LTCC class averages, each containing between 30 and 65 LTCC complexes
labeled with ConA. At pH 7, ConA forms a stable asymmetric tetramer (3–6
nm in size) binding to N-linked glycosylation sites. Selected particles were
subjected to alignment and classification methods with four of the principal
class averages presented. Class averages in panels 1 and 2 show putative
face-on viewsof the complexwith aConA tetramer associatedwith the finger
domain. The averaged images in panels 3 and 4 are side views of the complex
with ConA bound toward the tip of the complex. Box size 374 374 Å. The
white arrows indicate the “finger domain,” and the black arrows indicate the
additional ConA density attached.
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extend out from the main protein density. However, a compar-
ison of the two finds that the tail ismuch shorter than the finger
segment with a different orientation and angle of extension
from CaV3.1 when compared with the way in which the finger
domain protrudes out from the body of the cardiac LTCC.
Moreover, modeling of the two structures so that the finger
domain corresponds to theC terminus of CaV1.2 found that the
majority of the protein density would lie within the membrane,
which is not consistent with known topology, and conse-
quently, it would seem that this is not the case. Furthermore,
modeling of the two structures as shown in Fig. 7 shows that the
region attributed to the C-terminal domain of CaV1.2 will be
intimately associated with the -polypeptide and thus is likely
not resolved in the cardiac LTCC three-dimensional volume.
Murata et al. (47) first reported two-dimensional projection
images of negatively stained (uranyl acetate) monomeric rabbit
skeletal muscle LTCCs, describing a
rod-like structure with a height of
210 Å and diameter of 100 Å
with a small spherical domain
extending from the upper portion of
the rod. Labeling studies led to the
proposal that the skeletal muscle
channel spans the T-tubular mem-
brane by210 Å with the spherical
density corresponding to the 2
polypeptide placed on the extracel-
lular side. This work was followed
by the first three-dimensional struc-
ture of a skeletal muscle LTCC
monomer by Serysheva et al. (48)
determined from frozen hydrated
protein. However, the three-dimen-
sional volume was found to be sub-
stantially smaller (115  130 
120 Å), but the proposed orienta-
tion of the two principal domains,
termed a heart and a handle region,
agreed with that of Murata et al.
(47), with an asymmetric distribu-
tion of protein density across the
bilayer, consistent with the pre-
dicted topology. The three-dimen-
sional monomer structure for the
skeletal muscle LTCC described by
Wolf et al. (39) a year later was not
only larger than the other directly
comparable structure from Sery-
sheva et al. (48) but was positioned
so that the majority of the protein
density was within the membrane,
leaving only the leg domain extend-
ing into the extracellular milieu. On
the basis of labeling of the intracel-
lular and extracellular polypeptides
of the channel dimers studied by
this group, we proposed a similar
orientation of the skeletal and car-
diac dimer structures, with respect to the lipid bilayer, as that
suggested by the Murata (47) and Serysheva (48) groups and in
contrast to that proposed by Wolf et al. (39).
We have now advanced this work further and show a direct
comparison between the monomeric cardiac LTCC structure
described here and the skeletal muscle LTCC structure ofWolf
et al. (39), finding them to be very similar. Our new structure
shows that the finger extends out from the nose density that lies
directly above the domain ascribed to the CaV1.2 ion channel
pore subunit, and so, in agreement with our ConA labeling, we
suggest that this region is also attributable to a portion of the
2 protein. As shown in Fig. 7, fitting of the CaV3.1, KV1.2, and
-core crystal structures into the LTCC three-dimensional vol-
ume also allows the approximate region corresponding to 2
to be defined (Fig. 7, C–F) (due to the small size of the 
polypeptide, we cannot resolve it from 2). This region corre-
FIGURE 7. Cardiac LTCC three-dimensional structure, orientation and fitting of Cav3.1. A and B, LTCC
three-dimensional volume (pink mesh) with the three-dimensional volume of CaV3.1 (surface-rendered in tur-
quoise; transparency setting 0.7) with the TM domains represented by the crystal structure of KV1.2 (PDB entry
2A79) (TM domain,magenta ribbon) and the -core (blue ribbon) crystal structure in complex with the CaV1.2
AID peptide (PDB entry 1T3L) (red helix) fitted in the putative cytoplasmic domains. The CaV3.1 volume
matched to the lower portion of the LTCC three-dimensional structure, with the crystal structure of the trans-
membrane domain of KV1.2 (analogous to the TM region of both LVA and HVA channels) indicating the
putative position of the lipid bilayer. The crystal structure of the -core fits into a pocket formed by the
cytoplasmic domains of CaV3.1 and the narrow end of the LTCC volume. C, LTCC three-dimensional structure
surface-rendered in pink, with structures fitted as in A and B butwith CaV3.1 not shown to indicate the position
of a side hole in the outer surface of the LTCC volume, which also corresponds to a region of low density (a
perforation in the CaV3.1 volume) with the structures organized as shown here. The dashed line indicates a
possible route of Ca2 translocating across the plasma membrane. ex, extracellular; in, intracellular. D and E,
Similar views to those shown in A and B, respectively, but with only the putative position of the lipid bilayer
shown by the TM domain of KV1.2, permitting an outline of the extracellular 2 subunit to be visualized
(colored green). The CaV3.1 volume and -core crystal structure are still modeled within the LTCC but not
shown (using the Model panel in Chimera). F, side view of the cardiac LTCC illustrating how the complex has
beenorientatedby tilting the long axis of the complex50°with respect to theplaneof the lipid bilayer.G, top
view of the complex revealing further details of the organization of the2 polypeptide forming a cap over the
top of the CaV subunit but with the ion channel pore open to the extracellular milieu.
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sponds to a protein mass of 170 kDa (at the thresholds dis-
played here) andhas been colored green to give an impression of
the shape, size, and architecture of the 2 polypeptide. The
2 subunit forms a “cap” on the top of the CaV polypeptide,
and the view shown in Fig. 7G reveals that the pore of CaV1.2 is
open to the extracellular milieu below the 2. This arrange-
ment suggests that several extracellular domains of CaV1.2 are
likely to be engaged in binding 2. We have previously noted
that both the LTCC 2-subunit and many cell adhesion mole-
cules, including integrin -subunit, contain a Von Willebrand
factor-A domain with a metal ion-dependent adhesion site
motif and that integrin dimers form a loose hairpin structure
(15). It is therefore interesting to find that the details of the
finger domain shown here reveal that it also forms a hook-
shaped structure.
The new structure for CaV3.1 described here also allows us to
propose another orientation for the LTCC complex, whereby
the long axis traverses the plasma membrane as shown in Fig.
7F, tilted at an angle of 50° with respect to the plane of the
bilayer. An alternative orientation would be whereby the long
axis is orthogonal rather than tilted; however, this would place
a portion of the finger domain (which corresponds to the 2
polypeptide) within the lipid bilayer. Because this domain may
be quite flexible in its native environment in vivo, there may be
movement of the finger placing it above the membrane, and so
this orientation cannot be discounted. An alternative interpre-
tationwould be one in which the finger domain corresponds, in
part, to the transmembrane , but because only a single helix is
suggested to span the membrane, then the volume of the finger
domain (even accounting for associating detergent) ismuch too
large. Therefore, on the basis of the data we currently have
available, we propose the orientation as shown in Fig. 7,C andF.
The model in Fig. 7 places the HVA -subunit nestled
between the base of the CaV3.1 with the C terminus wrapped
around and the AID domain in close proximity to the TM
assembly. This arrangement helps explain how the -polypep-
tide may bind to CaV1.2 because in addition to the interaction
domain crystallized with the -subunit (AID), there are multi-
ple reports of other interaction sites between  and 1, which
would be consistent with the -subunit fitting, in part, into the
pocket formed by the cytoplasmic domains of CaV3.1. For
example, the N terminus (49), regions between loops I-II (50)
and III-IV (51), and the C terminus (52) of various 1 polypep-
tides have all been implicated in interactions with the -sub-
unit. The -polypeptide as shown here is exposed to the cyto-
plasm from the base of the structure and thus is also able to bind
regulatory proteins (53). This arrangement leads to a region of
low density identified in the surface-rendered LTCC volume,
Fig. 5, B and C, labeled hole, and thus it is tempting to suggest
that this organization of polypeptides forms a tunnel leading to
the interior of the structure and may be the exit route for Ca2
from the LTCC into the cytosol after translocation across the
lipid bilayer passing through the ion channel as illustrated in
Fig. 7C.
Our study presents the first three-dimensional structure of a
T-type voltage-gated calcium channel. T-type channels are
critical components of a multitude of fundamental physiologi-
cal processes.However, themechanisms underlying LVAchan-
nel regulation and control are still largely unknown, and thus
the structure presented here, and details resolved, represent an
important step forward to closing the gaps in current knowl-
edge and pave the way for future structure-function studies.
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